<DOC>
	<DOCNO>NCT00575094</DOCNO>
	<brief_summary>To purpose study assess safety tolerability intravenous ( IV ) tigecycline hospitalize subject Japanese descent community-acquired pneumonia ( CAP ) .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Intravenous Tigecycline Treat Hospitalized Japanese Subjects</brief_title>
	<detailed_description>This multicenter , open-label study evaluate safety efficacy tigecycline treatment Japanese subject CAP . Subjects clinical sign symptom CAP meet eligibility requirement consider enrollment . Qualifying subject assign receive tigecycline via IV administration 7 14 consecutive day . The exact duration administration study drug discretion investigator , base subject 's condition . Subjects follow safety test-of-cure ( TOC ) assessment 10 21 day last dose therapy , efficacy TOC assessment .</detailed_description>
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Hospitalized Japanese descent subject know suspected CAP severity require IV antibiotic treatment . Chest radiograph within 48 hour first dose IV test article show presence new infiltrate . The presence fever hypothermia within 24 hour first administration test article , least two signs/symptoms CAP within 24 hour first administration test article . Any concomitant condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy could complete . Hospitalacquired pneumonia , lung disease include viral , fungal , parasitic pneumonia , immunosuppressive condition , illness , affect evaluation safety efficacy tigecycline . Known suspected hypersensitivity tigecycline tetracycline , contraindication antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>